Background
The COVID-19 pandemic has led to the rapid development of new vaccines and
Conclusions
Collectively, our data provide the insights into antibody avidity maturation after the adenovirus-based vaccines against SARS-CoV-2.
Methods
The avidity of RBD-specific IgGs and IgAs was investigated through ELISA using urea and biolayer interferometry.
Results
The results demonstrated the similar avidities of serum antibodies, which were induced by both vaccines for six months post-booster. However, an increase in antibody avidity was observed for the wild-type and Delta variants, but not for the BA.4/5 variant. Conclusions: Collectively, our data provide the insights into antibody avidity maturation after the adenovirus-based vaccines against SARS-CoV-2.